All In Biotech

Drug Trial Radar · NCT05743881

A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months

A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months

Last checked: Nov 20, 2026Latest source record: Jun 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 186 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

186

Actual

Start

Feb 15, 2023

Primary completion

Aug 31, 2029

Study completion Aug 31, 2029

Sponsor

Lead sponsor
ModernaTX, Inc.Moderna (MRNA)
Sponsor type
Industry
First posted
Feb 24, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 5 months, up to 24 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety and immunogenicity of mRNA-1365, an mRNA vaccine targeting respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) and mRNA-1345, an mRNA vaccine targeting RSV, in participants aged 5 months to \<24 months.

Conditions

  • Respiratory Syncytial Virus
  • Human Metapneumovirus

Interventions

  • mRNA-1345Biological

    Sterile liquid for injection

  • mRNA-1365Biological

    Sterile liquid for injection

  • PlaceboBiological

    0.9% sodium chloride (normal saline) solution for injection

  • NimenrixDrug

    Solution for injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Main Study: Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs)Time frame: Up to Day 120 (7 days after each injection)
  2. Main Study: Number of Participants with Unsolicited Adverse Events (AEs)Time frame: Up to Day 141 (28 days after each injection)
  3. Main Study: Number of Participants with Medically-Attended Adverse Events (MAAEs)Time frame: Day 1 through Day 730
  4. Main Study: Number of Participants with Adverse Event of Special Interests (AESIs), Serious Adverse Events (SAEs) and Adverse Events Leading to DiscontinuationTime frame: Day 1 through Day 730
  5. Part B Extension: Number of Participants with MAAEs, AESIs and SAEsTime frame: Day 1 of the Extension to end of study (EoS) (up to 3 years)
  6. Part B Extension: Number of Participants with Lower Respiratory Tract Illness (LRTI), Severe LRTI, Very Severe LRTI, and Hospitalizations Associated with RSV or hMPVTime frame: Day 1 of the Extension to EoS (up to 3 years)

Locations

17 sites in 3 countries. Site status is shown where the registry gives one.

  • Matrix Clinical Research

    Los Angeles, California

  • Meridian Clinical Research

    Washington D.C., District of Columbia

  • DM Clinical Research- River Forest

    Melrose Park, Illinois

  • MedPharmics - Platinum - PPDS

    Lafayette, Louisiana

  • Duke Vaccine and Trials Unit

    Durham, North Carolina

  • Velocity Clinical Research - Providence

    Providence, Rhode Island

  • Palmetto Pediatrics, PA

    North Charleston, South Carolina

  • Vanderbilt Vaccine Research Program

    Nashville, Tennessee

  • CyFair

    Houston, Texas

  • Pediatric Associates

    Houston, Texas

  • Village Pediatrics

    Plano, Texas

  • Pediatric Center

    Richmond, Texas

  • CEVAXIN Avenida Mexico

    Panama City, Panama

  • CEVAXIN 24 de Diciembre

    Panama City, Panama

  • CEVAXIN David

    David, Chiriquí Province, Panama

  • CEVAXIN Chorrera

    La Chorrera, Panamá Oeste Province, Panama

  • Norfolk and Norwich University Hospitals

    Norwich, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.